临床试验研究设计终点和生物标志物药物安全性

关键字：类型：

下载页码(大于等于0,小于611)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)

minimal residual disease,317–320 317 320

Acute myeloid leukemia (AML)clinical features,289–291 289 291

cytogenetics for diagnosis and prediction,300–302 300 302

Acute promyelocytic leukemia (APL),291–292,323 291 292 323

ADCC see Antibody-dependent cell cytotoxicity Add-on design active control,45 45

Adjuvant therapy advantages over neoadjuvant therapy chronic drug administration,276 276

metastasis risk reduction,275 275

staging accuracy,276 276

meanings of adjuvant,276–277 276 277

neoadjuvant therapy advantages see Neoadjuvant therapy overview,271–272 271 272

Adverse event (AE)adverse drug reaction,425 425

anticipation in clinical study design,419–420 419 420

cause-and-effect data from raw data,435–436 435 436

classification anticipated versus unanticipated,431–435 431 435

disease induction versus study drug induction,426–427 426 427

statistician considerations,427 427

Dear Healthcare Professional letters in risk minimization acne medications,456–457 456 457

appetite suppressants,457 457

birth control pills,455–456 455 456

example,454–455 454 455

overview,452–454 452 454

definitions,423–426 423 426

dose modification,420–423 420 423

examples,418–419 418 419

intent to treat analysis,427–431 427 431

mechanism of action and expected adverse drug reactions,473–474 473 474

monitoring and evaluation Case Report Form follow up reports,446–447 446 447

writing style,444–445 444 445

CTCAE dictionary,442 442

data capturing transmission and evaluation,445–449 445 449

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：